Magnus Life Science

Biopharma, Biotechnology, Life Science
Founded in 2013-01-01
London, England, United Kingdom
For Profit

About Magnus Life Science

Magnus Life Science: Where Blood Flow Matters Human disease will only be conquered by new ideas. Magnus has those ideas and employs a novel approach to the advancement and rapid development of valuable new discoveries in biomedicine. Every organ depends on the quality and quantity of the blood delivered to it. Disease is caused by interference with this process. Magnus Science has identified how to restore natural processes and establish health. This approach has come out of many years of deep research in one of the world’s leading universities, University College London. These ideas are completely original and powerful. Magnus has developed these ideas into new treatments for fetal conditions, heart disease and cancer which will be taken into patients in a rapid and focused way by Magnus scientists who are also practicing clinicians.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 15500000 GBP
  • Last Funding: 15500000 GBP (Private Equity)
  • Funding Status: Private Equity

Technology Stack

Magnus Life Science actively uses None products in their tech stack.

Market Presence

Industries: Biopharma, Biotechnology, Life Science

Headquarters: London, England, United Kingdom